The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
white-paper
A Novel Power BI Tool to Monitor Change Controls and Key Performance Indicators
Read More
white-paper
Optimizing Clinical Supply Chain Management
Read More
post
The Importance of Stability Studies in CMC Compliance
Read More
post
Understanding the FDA’s Evolving Expectations for Biopharma Compliance
Read More
Let's move from science to success.
Let’s Talk